论文部分内容阅读
目的 探讨ＣＹＦＲＡ２１１，ＣＥＡ和Ｇａｓｔｒｉｎ 组合动态检测在肺癌诊断，分型分期，疗效观察和预后判断的临床价值。方法 选自本院３１ 例肺癌，２８ 例肺部良性疾病住院患者和２８例本院健康志愿者，应用放射免疫分析法（ＩＲＭＡ）检测血清ＣＹＦＲＡ２１１，ＣＥＡ水平；应用放射免疫～ＰＥＧ法检测血清ＣＥＡ和Ｇａｓｔ．水平。肺癌患者在化疗和／或放疗１～２个疗程前后各检测一次。以本院同位素实验室提供的临界值为依据：血清ＣＹＦＲＡ２１１，ＣＥＡ 和Ｇａｓｔ水平分别为３．３ｎｇ／ｍ ｌ，１５ｎｇ／ｍ ｌ和１００ｐｇ／ｍ ｌ。结果 肺癌组患者血清ＣＹＦＲＡ２１１，ＣＥＡ和ＣＹＦＲＡ２１１显著高于良性肺部疾病组（Ｐ＜０．０１）和健康组（Ｐ＜ ０．０１）；按肺癌组织分型分析，血清ＣＹＦＲＡ２１１，ＣＥＡ和Ｇａｓｔ对各类肺癌诊断阳性率最高的分别为Ｓｑ．Ｃ（８３．３％ ），Ａｄ．Ｃ．（８１．８％ ）和Ｓ．Ｃ．Ｌ．Ｃ．（１００％ ）；就肺癌的ＴＮＭ 分期来看，上述三种肿瘤标记物的水平与临床分期呈一致性改变（Ⅳ期＞ Ⅲ期＞ Ⅱ期）；经化疗和／或放疗后，上述肿瘤标记物水平均有不同幅度的下降，但最能从下降幅度体现疗效的仍然是：ＣＹＦＲＡ２１?
Objective To explore the clinical value of dynamic detection of CYFRA211, CEA, and Gastrin in the diagnosis, classification, clinical efficacy, and prognosis of lung cancer. The method was selected from 31 patients with lung cancer in our hospital, 28 hospitalized patients with benign lung diseases and 28 healthy volunteers in our hospital. Serum CYFRA211 and CEA levels were detected by radioimmunoassay (IRMA); radioimmunoassay was used to detect PEG. Serum CEA and Gast. Level. Lung cancer patients were tested before and after 1 to 2 cycles of chemotherapy and/or radiotherapy. Based on the cutoff value provided by the isotope laboratory of our hospital, serum CYFRA21 1, CEA and Gast levels were 3.3 ng/ml, 15 ng/ml and 100 pg/ml, respectively. Results Serum CYFRA211, CEA and CYFRA211 in patients with lung cancer were significantly higher than those in benign lung disease group (P<0.01) and healthy group (P<0.01). According to lung cancer tissue typing, serum CYFRA21 1, CEA and Gast have the highest positive rates for the diagnosis of various types of lung cancer. C (83.3%), Ad. C. (81.8%) and S. C. L. C. (100%); For the TNM staging of lung cancer, the levels of the above three tumor markers are consistent with the clinical stage (IV>III>II); after chemotherapy and/or radiotherapy, the above tumor markers There is a drop in the average water content, but the most effective way to reflect the effect is: CYFRA21?